From In Silico to Clinic: Harnessing Noncoding RNAs for Diabetes Research and Therapy, a Step toward ncRNA Precision.

Diabetes mellitus (DM) represents a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia and progressive metabolic dysregulation, arising from distinct but overlapping pathogenic mechanisms. Emerging evidence positions noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), circular RNAs (circRNAs), and P-element-induced WImpy testis-interacting RNAs (piRNAs), as central regulators of pancreatic β-cell integrity, insulin signaling, immune modulation, and metabolic homeostasis. This comprehensive review synthesizes current mechanistic and translational insights into ncRNA biogenesis, regulatory networks, and functional roles across diverse DM subtypes, including type 1, type 2, latent autoimmune diabetes in adults, gestational, monogenic, and the recently recognized type 5 diabetes. Through systematic in silico integration of curated databases (e.g., HMDD v4.0 and LncRNADisease) with experimental evidence, we map disease-specific ncRNA signatures and delineate their regulatory axes in β-cell dysfunction, insulin resistance, inflammatory signaling, and diabetic complications. Increasing data support the clinical relevance of distinct circulating and tissue-specific ncRNAs as minimally invasive biomarkers for early detection, subtype stratification, prognosis, and prediction of therapeutic response. Moreover, mechanistic studies highlight ncRNA-mediated pathways as actionable targets for RNA-based therapeutics and precision medicine strategies, particularly in autoimmune-driven β-cell destruction and metabolic insulin resistance. By bridging computational network analyses with molecular and clinical evidence, this review advances an integrated framework for ncRNA-guided diabetes diagnostics and targeted intervention. We further identify critical methodological and validation gaps that must be addressed to accelerate the translation of ncRNA discoveries from bench to bedside, underscoring their transformative potential in reshaping DM management.